|
|
|
|
- NSIV Member Spotlight - IVIVA Medical
- NSIV Markets Soft Landings Program
- Events, News and Updates
|
|
|
|
|
Find all these stories and more on our website! Stay informed at NSIV.org.
|
|
|
|
|
|
|
NSIV Member Spotlight - IVIVA Medical
|
|
End-stage renal disease, or  kidney failure, affects over 500,000 patients in the United States. A transplant is the only definitive treatment, yet most patients spend years on the waitlist with little hope of receiving a donor kidney in time. IVIVA Medical could revolutionize this longstanding issue by creating an artificial kidney — a device manufactured in a laboratory that functions as an organ and is immunologically matched to any patient.
IVIVA was founded as the result of work coming out of Dr. Harald Ott’s lab at MGH. There, the team of researchers has developed a process called decellularization, by which an organ...more
|
|
NSIV Markets Soft Landings Program
|
|
Recent newsletters have been keeping you informed about
- NSIV's Soft Landing Program, designed to help international companies adapt and thrive in the U.S. business environment,
- InBIA's award designating NSIV as part of their important Soft Landings Directory (see the full press release here), and
- Recent efforts to promote this type of program as part of the three week 2018 Boston Immersion Program in October.sponsored by the Richi Entrepreneurs in partnership with ACTION Innovation Network.
This month, we'd like to explain more about what this means. In October, five companies from Germany's Medical Valley EMN came to the U.S., with a first stop in NYC and then on to Boston for a visit with NSIV. The companies included Sanolibio, Unitdoseone, Inveox, Mercuris, and Nice Innovation. NSIV is a Soft Landing partner to Medical Valley - you'll see our logo on their website and theirs on our site. 
Medical Valley is an organization similar to NSIV which provides consulting and support for incubated companies. Many of these companies are looking to expand their sales to an American market, and so they have been visiting major cities to determine the best markets for their products. Boston happens to be the closest city to Europe, and it’s also the best city for biotechnology, hospitals and education. NSIV provides a close-by alternative to the city, offering affordable office space and lab equipment. sponsored professional services, successful entrepreneur mentors, and investor advisers. Medical Valley's companies, such as NICE Innovations, are eager to move to the Boston area. However, the companies must carefully plan their market entry and find employees that are willing to help run a US location.
Also in October, we saw the launch of InBIA's ENRICH program with the opening of the East Coast Centre in Boston at the Cambridge Innovation Center (CIC). ENRICH stands for European Network of Research and Innovation Centres and Hubs and their program objective is to "connect and foster European researchers and innovators with US opportunities." Some of the participants gathered for the opening also came out to Beverly to learn more about NSIV.
And from the 2018 Boston Immersion Program mentioned above, NSIV later hosted five companies that had traveled from Italy, Spain and Chile.
It has certainly been a busy fall, with many opportunities to meet entrepreneurs interested in the U.S. market and showcase the Soft Landings Program offered by NSIV.
|
|
Still time to apply: Massachusetts Life Sciences Center Milestone Achievement Program (MAP) is designed to address the needs of early-stage life sciences companies by providing grant funding to execute critical, value-creating technical milestones. This program aims to fill a gap within the existing funding environment to enable early stage companies to attract additional follow on funding. The Deadline to apply is December 14, 2018 - find all the details.
And if you have been planning to read The National Climate Assessment, the more than 1000 page report summarizing the impacts of climate change on the United States, now and in the future, we've provided the link.
|
|
|
|
|
|
|
|
|
